Hospira

Activities: Drug Delivery Pharmaceutical

Trending Articles

  1. Poolbeg Pharma trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme Poolbeg will act as the lead business partner, alongside Johnson & Johnson and other partners, on the University of Manchester and The Christie NHS Foundation Trust research...
  2. Manufacturing Chemist Stand Side with Piramal Pharma Solutions We discover what exhibitors at CPHI 2025 are showcasing LIVE!
  3. SGS achieves breakthrough in infectious disease research with launch of novel RSV A-strain Derived from a 2015 circulating strain, SGS's novel RSV-A challenge agent offers a closer match to circulating RSV viruses than strains currently used in clinical research
  4. One in four European pharma companies at risk of regulatory breaches according to NSF research The independent survey exposed significant gaps in quality systems, supply chain oversight and data integration, just as EU GMP regulations continue to tighten
  5. IWK introduces machine to produce 100% cardboard blister packaging CABLIblue 870 features innovative “card-to-card” technology for recyclable, fiber-based blisters

Upcoming event

From powder to granules: a deep dive into wet granulation methods

14 January 2026 | Virtual See all

Related Content

Regulatory

FDA cautions Pfizer subsidiary in India in quality control warning letter

The letter is the result of an inspection at Hospira Healthcare India that identified GMP violations in quality control, data integrity, and microbial control
Drug Delivery

Mylan and Hospira voluntarily recall injectables

Glass and copper salts were found in the companies’ injectable medications but no adverse reactions have been reported as yet
Regulatory

Brussels explains why it approved Pfizer/Hospira deal

Pfizer made a commitment to remove possible product overlaps between the two companies
Regulatory

Hospira calls for biosimilars to have same name as biologicals

Different names for a biologic and the biosimilar medicine patterned on that biologic could create confusion among clinicians
Research & Development

Hospira and Pfenex link up to develop Lucentis biosimilar

Pfenex will receive US$51m upfront once the collaboration receives antitrust approval
Drug Delivery

Pfizer to acquire Hospira

Pfizer and Hospira have entered into a definitive merger agreement under which Pfizer will acquire Hospira
Manufacturing

Opinion: Still not getting it right

The future for pharma development is bright, but there are still too many potentially dangerous recalls in the manufacturing sector
Subscribe now